Prognostic role of serum C-reactive protein in patients with
advanced-stage NSCLC treated with pemetrexed

J 2017

Prognostic role of serum C-reactive protein in patients with advanced-stage NSCLC treated with pemetrexed

FIALA, O.; P. HOSEK; M. PESEK; J. FINEK; J. RACEK et. al.

Základní údaje

Originální název

Prognostic role of serum C-reactive protein in patients with advanced-stage NSCLC treated with pemetrexed

Autoři

FIALA, O. (203 Česká republika); P. HOSEK (203 Česká republika); M. PESEK (203 Česká republika); J. FINEK (203 Česká republika); J. RACEK (203 Česká republika); T. BUCHLER (203 Česká republika); Alexandr POPRACH (203 Česká republika, domácí); Karel HEJDUK (203 Česká republika, garant, domácí); Renata CHLOUPKOVÁ (203 Česká republika, domácí); O. SOREJS (203 Česká republika); M. ECKSTEINOVA (203 Česká republika); M. VITOVEC (203 Česká republika); K. CIZKOVA (203 Česká republika); R. KUCERA (203 Česká republika) a O. TOPOLCAN (203 Česká republika)

Vydání

Neoplasma, Bratislava, Slovenská akademie vied, 2017, 0028-2685

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Slovensko

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 1.696

Kód RIV

RIV/00216224:14110/17:00097428

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.4149/neo_2017_416

UT WoS

000407539900016

EID Scopus

2-s2.0-85024100327

Klíčová slova anglicky

C-reactive protein; lung cancer; NSCLC; chemotherapy; pemetrexed; prognosis

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 20. 3. 2018 14:03, Soňa Böhmová

Anotace

V originále

Pemetrexed is an intravenously administered antifolate cytostatic agent targeting several folate-dependent enzymatic pathways, widely used in the treatment of patients with advanced non-small cell lung cancer (NSCLC). It has been previously demonstrated that the superiority of pemetrexed is limited to patients with non-squamous histology. Aside from the non-squamous histology, there is still no available molecular biomarker predicting treatment efficacy of pemetrexed-based chemotherapy. The aim of our retrospective study was to evaluate the association of baseline serum levels of C-reactive protein (CRP) with outcomes in a large cohort of patients with non-squamous NSCLC treated with pemetrexed. Clinical data of 325 patients were analysed. Serum samples were collected within one week before the initiation of treatment. The median progression-free (PFS) and overall survival (OS) for patients with high CRP was 2.1 and 9.5 compared to 4.2 and 20.5 months for those with normal CRP (p=0.002 and p<0.001, respectively). The multivariable Cox proportional hazards model revealed that serum CRP (HR=1.46, p=0.002) was significantly associated with PFS and also with OS (HR=1.95, p<0.001). In conclusion, the study results suggest that pretreatment serum CRP is associated with poor outcome of non-squamous NSCLC patients treated with pemetrexed.

Citovat

FIALA, O.; P. HOSEK; M. PESEK; J. FINEK; J. RACEK; T. BUCHLER; Alexandr POPRACH; Karel HEJDUK; Renata CHLOUPKOVÁ; O. SOREJS; M. ECKSTEINOVA; M. VITOVEC; K. CIZKOVA; R. KUCERA a O. TOPOLCAN. Prognostic role of serum C-reactive protein in patients with advanced-stage NSCLC treated with pemetrexed. Neoplasma. Bratislava: Slovenská akademie vied, 2017, roč. 64, č. 4, s. 605-610. ISSN 0028-2685. Dostupné z: https://dx.doi.org/10.4149/neo_2017_416.

@article{1388308,
   author = {Fiala, O. and Hosek, P. and Pesek, M. and Finek, J. and Racek, J. and Buchler, T. and Poprach, Alexandr and Hejduk, Karel and Chloupková, Renata and Sorejs, O. and Ecksteinova, M. and Vitovec, M. and Cizkova, K. and Kucera, R. and Topolcan, O.},
   article_location = {Bratislava},
   article_number = {4},
   doi = {http://dx.doi.org/10.4149/neo_2017_416},
   keywords = {C-reactive protein; lung cancer; NSCLC; chemotherapy; pemetrexed; prognosis},
   language = {eng},
   issn = {0028-2685},
   journal = {Neoplasma},
   title = {Prognostic role of serum C-reactive protein in patients with advanced-stage NSCLC treated with pemetrexed},
   volume = {64},
   year = {2017}
}

TY  - JOUR
ID  - 1388308
AU  - Fiala, O. - Hosek, P. - Pesek, M. - Finek, J. - Racek, J. - Buchler, T. - Poprach, Alexandr - Hejduk, Karel - Chloupková, Renata - Sorejs, O. - Ecksteinova, M. - Vitovec, M. - Cizkova, K. - Kucera, R. - Topolcan, O.
PY  - 2017
TI  - Prognostic role of serum C-reactive protein in patients with advanced-stage NSCLC treated with pemetrexed
JF  - Neoplasma
VL  - 64
IS  - 4
SP  - 605-610
EP  - 605-610
PB  - Slovenská akademie vied
SN  - 00282685
KW  - C-reactive protein
KW  - lung cancer
KW  - NSCLC
KW  - chemotherapy
KW  - pemetrexed
KW  - prognosis
N2  - Pemetrexed is an intravenously administered antifolate cytostatic agent targeting several folate-dependent enzymatic pathways, widely used in the treatment of patients with advanced non-small cell lung cancer (NSCLC). It has been previously demonstrated that the superiority of pemetrexed is limited to patients with non-squamous histology. Aside from the non-squamous histology, there is still no available molecular biomarker predicting treatment efficacy of pemetrexed-based chemotherapy. The aim of our retrospective study was to evaluate the association of baseline serum levels of C-reactive protein (CRP) with outcomes in a large cohort of patients with non-squamous NSCLC treated with pemetrexed. Clinical data of 325 patients were analysed. Serum samples were collected within one week before the initiation of treatment. The median progression-free (PFS) and overall survival (OS) for patients with high CRP was 2.1 and 9.5 compared to 4.2 and 20.5 months for those with normal CRP (p=0.002 and p<0.001, respectively). The multivariable Cox proportional hazards model revealed that serum CRP (HR=1.46, p=0.002) was significantly associated with PFS and also with OS (HR=1.95, p<0.001). In conclusion, the study results suggest that pretreatment serum CRP is associated with poor outcome of non-squamous NSCLC patients treated with pemetrexed.
ER  -

FIALA, O.; P. HOSEK; M. PESEK; J. FINEK; J. RACEK; T. BUCHLER; Alexandr POPRACH; Karel HEJDUK; Renata CHLOUPKOVÁ; O. SOREJS; M. ECKSTEINOVA; M. VITOVEC; K. CIZKOVA; R. KUCERA a O. TOPOLCAN. Prognostic role of serum C-reactive protein in patients with advanced-stage NSCLC treated with pemetrexed. \textit{Neoplasma}. Bratislava: Slovenská akademie vied, 2017, roč.~64, č.~4, s.~605-610. ISSN~0028-2685. Dostupné z: https://dx.doi.org/10.4149/neo\_{}2017\_{}416.

Přehled o publikaci